[display_podcast]
Date: October 8th, 2015
Guest Skeptic: Meghan Groth (@EMPharmGirl). Meghan is the emergency medicine pharmacy specialist at the University of Vermont Medical Center in Burlington, Vermont and an adjunct professor of pharmacy at the Albany College of Pharmacy and Health Sciences.
Case: A 26-year-old male presents to your emergency department with complaints of a painful, reddened area on his right arm. He has no significant past medical history, surgical history, or social history, but reports that he has an allergic reaction to penicillin and cephalosporin antibiotics.
On exam, you find an abscess approximately 6cm in diameter with surrounding cellulitis. After performing an incision and drainage, you contemplate sending the patient home with a prescription for antibiotic therapy.
The patient expresses to you that he’s seen cases of MRSA (methicillin-resistant Staphylococcus aureus) reported on the news and is worried this may be involved in his infection.
Background: Skin and soft tissue infections (SSTIs) are a common reason for visits to the emergency department, hospital admissions, and may result in considerable morbidity and mortality.
Classically, it has been thought that beta-hemolytic Streptococci are the causative organisms for cellulitis and Staph species are commonly implicated in cases of skin abscesses.
More recently, MRSA has been recognized as a common cause of SSTIs.
Clinical Question: For patients with uncomplicated skin infections, is clindamycin superior to trimethoprim-sulfamethoxazole?
Reference: Miller LG, et al. Clindamycin versus trimethoprim-sulfamethoxazole for uncomplicated skin infections. NEJM 2015
* Population: Adult and paediatric patients aged six months to 85 years with at least two of the following for 24 hours or more: erythema, swelling/induration, local warmth, purulent drainage, and tenderness to pain/palpation.
* Exclusions: (supplementary index that was three pages long) Body site involvement requiring special management (e.g. perirectal, genital, or hand), human or animal bites, high fever, immunosuppression, diabetes, chronic renal failure, morbid obesity, surgical site infections, or receipt of antibiotics within 14 days that included anti-staphylococcal activity, residence in a long term care facility, cancer, or major surgery in the previous 12 months.
* Intervention: Clindamycin 300 mg PO TID x 10 days (or weight-based paediatric dose)
* Comparison: TMP-SMX 160-800 mg x 10 days BID (or weight-based paediatric dose)
* Outcome:
* Primary Outcome: Clinical cure at the test of cure (TOC) visit (7-10 days after completion of antibiotic course).
* Secondary Outcome: Patients were also evaluated at the end of treatment at 30 days post 10 day antibiotic course (day 40) for symptom resolution and for medication-related adverse effects.
Authors’ Conclusions: “We found no significant differences between the efficacy of clindamycin and that of TMP-SMX for the treatment of uncomplicated skin infections in children and adults with few or no major coexisting conditions.”
Quality Check for Randomized Clinical Trials:
* The study population included or focused on those in the ED. No. Patients were recruited from urgent care clinics, emergency departments, and clinics affiliated with the four medical centers involved.
* The patients were adequately randomized. Yes
* The randomization process was concealed. Yes
* The patients were analyzed in the groups to which they were randomized. Yes
* The study patients were recruited consecutively (i...